| Literature DB >> 31662902 |
Ze Zheng1, Zi Chao Cheng1, Shao Ping Wang1, Shi Ying Li1, Jian Wang1, Hong Yu Peng1, Zheng Wu1, Wen Zheng Li1, Yun Lv1, Jia Yu Tian1, Shu Juan Cheng1, Jing Hua Liu1.
Abstract
OBJECTIVES: Chronic total occlusion (CTO) is prevalent in patients with prior coronary artery bypass grafting (CABG). However, data available concerning the prevalence of new-onset CTO of native vessels in patients with prior CABG is limited. Therefore, the objective of the study is to determine predictors for new native-vessel occlusion in patients with prior coronary bypass surgery.Entities:
Year: 2019 PMID: 31662902 PMCID: PMC6778907 DOI: 10.1155/2019/6857232
Source DB: PubMed Journal: Cardiol Res Pract ISSN: 2090-0597 Impact factor: 1.866
Figure 1Flow chart of the study.
Baseline patient characteristics.
| Variables | All ( | No new CTO ( | New CTO ( |
|
|---|---|---|---|---|
| Age (yrs.) | 61.71 ± 9.47 | 62.75 ± 7.93 | 61.80 ± 8.38 | 0.492 |
| <65 (%) | 212 (59.89%) | 136 (59.64%) | 76 (60.31%) | |
| 65 to <75 (%) | 142 (40.11%) | 92 (40.35%) | 50 (39.68%) | |
| Sex | 0.694 | |||
| Male | 264 (74.58%) | 169 (74.12%) | 95 (75.40%) | |
| Female | 90 (25.42%) | 59 (25.88%) | 31 (24.60%) | |
| BMI (kg/m2) | 26.57 ± 3.88 | 27.06 ± 2.97 | 26.59 ± 3.48 | 0.397 |
| ≤18.4 | 0 | 0 | 0 | |
| 18.5–23.9 | 54 (15.25%) | 30 (13.16%) | 24 (19.05%) | |
| 24.0–27.9 | 186 (52.54%) | 125 (54.82%) | 61 (48.41%) | |
| ≥28 | 112 (31.64%) | 72 (31.58%) | 40 (31.75%) | |
| Hypertension | 248 (70.06%) | 158 (69.30%) | 90 (71.43%) | 0.532 |
| Hypercholesterolemia | 206 (58.19%) | 129 (56.59%) | 77 (61.11%) | 0.217 |
| Diabetes mellitus | 140 (39.55%) | 87 (38.16%) | 62 (49.20%) | 0.044 |
| Diet-controlled | 10 (7.14%) | 6 (6.90%) | 4 (6.45%) | |
| Tablet-controlled | 64 (45.71%) | 39 (44.82%) | 30 (48.39%) | |
| Insulin treatment | 66 (47.15%) | 42 (48.28%) | 28 (45.16%) | |
| Smoker |
| |||
| Never | 112 (31.64%) | 79 (34.64%) | 33 (26.19%) | |
| Former | 144 (40.68%) | 111 (48.68%) | 33 (26.19%) | |
| Current | 98 (27.68%) | 38 (16.67%) | 60 (47.62%) | |
| Prior MI | 90 (25.42%) | 58 (25.44%) | 32 (25.40%) | 0.990 |
| Prior PCI | 68 (19.21%) | 47 (20.61%) | 21 (16.67%) | 0.178 |
| Prior cardiac surgery | 2 (0.57%) | 2 (0.88%) | 0 (0.00%) | 0.525 |
| Prior heart failure | 36 (10.17%) | 21 (9.21%) | 15 (11.91%) | 0.237 |
| Peripheral vascular disease | 74 (20.90%) | 45 (19.74%) | 29 (23.02%) | 0.279 |
| 70 (19.77%) | 46 (20.18%) | 24 (19.05%) | 0.704 | |
| Cerebrovascular disease | 24 (6.78%) | 14 (6.14%) | 10 (7.94%) | 0.337 |
| Family history of CAD | 80 (22.60%) | 52 (22.81%) | 28 (22.22%) | 0.345 |
| Atrial fibrillation/flutter | 36 (10.17%) | 18 (7.90%) | 18 (14.29%) | 0.480 |
| 0.104 | ||||
| Presentation of ACS | 12 (3.39%) | 8 (3.51%) | 4 (3.17%) | |
| CCS class of angina | 218 (61.58%) | 145 (63.60%) | 73 (57.94%) | |
| Grade 1 | 110 (31.07%) | 68 (29.82%) | 42 (33.33%) | |
| Grade 2 | 14 (3.69%) | 8 (3.51%) | 6 (2.78%) | |
| Grade 3 | 58.43 ± 0.08% | 59.28% ± 0.07% | 56.89% ± 0.1% | 0.010 |
| Grade 4 | 11 (3.10%) | 3 (1.32%) | 8 (6.35%) | |
| Ejection fraction (%) | 31 (8.76%) | 14 (6.14%) | 17 (13.49%) | |
| ≤40% | 312 (88.14%) | 211 (92.54%) | 101 (80.16%) | |
| 40%–50% | 0.404 | |||
| ≥50% | 150 (42.37%) | 101 (44.30%) | 49 (38.89%) | |
| Left ventricular grade | 164 (46.33%) | 100 (43.86%) | 64 (50.79%) | |
| Class I | 38 (10.73%) | 26 (11.40%) | 12 (9.52%) | |
| Class II | 2 (0.57%) | 2 (0.88%) | 0 (0.00%) | |
| Class III | 77.6 ± 20.47 | 73.93 ± 17.94 | 79.09 ± 21.30 | 0.079 |
| Class IV | 87.2 ± 22.49 | 90.5 ± 20.11 | 85.89 ± 23.33 | 0.172 |
| Creatinine ( | 38 (10.73%) | 51.19 ± 7.03 | 46.46 ± 11.85 | 0.484 |
| GFR (ml/min/1.73 m2) | 2.47 ± 4.27 | 3.01 ± 4.40 | 2.26 ± 4.22 | 0.700 |
| GFR < 60 ml/min/1.73 m2 | ||||
| Hs-CRP (mg/L) |
Procedural and angiographic characteristics of patients with or without a new CTO.
| Variables | No new CTO ( | New CTO ( |
|
|---|---|---|---|
| Preoperative angiogram | |||
| Vessel stenosis at baseline | 0.001 | ||
| Moderate (40%–69%) | |||
| LAD | 18 (7.89%) | 7 (5.56%) | |
| LCX | 18 (7.89%) | 6 (4.76%) | |
| RCA | 22 (9.65%) | 9 (7.14%) | |
| Severe (≥70%) | |||
| LAD | 174 (76.32%) | 114 (90.48%) | |
| LCX | 123 (53.95%) | 89 (70.63%) | |
| RCA | 132 (57.89%) | 98 (77.78%) | |
| Coronary lesion category | 0.775 | ||
| Single-vessel disease | 18 (7.89%) | 8 (6.35%) | |
| Double-vessel disease | 62 (27.19%) | 31 (24.60%) | |
| Triple-vessel disease | 116 (64.47%) | 87 (69.05%) | |
| Left main involvement | 102 (44.74%) | 48 (38.10%) | 0.508 |
| Total no. of patients with ≥1 CTO | 83 (36.40%) | 44 (34.92%) | 0.416 |
| Total of CTO vessel | 0.984 | ||
| LAD | 23 (10.09%) | 15 (11.91%) | |
| LCX | 15 (6.58%) | 7 (5.56%) | |
| RCA | 35 (15.35%) | 18 (14.29%) | |
| Multivessel | 8 (3.51%) | 3 (2.38%) | |
| Mean no. of bypass grafts | 3.0 ± 0.63 | 3.06 ± 0.75 | 0.599 |
| Types of graft | 0.460 | ||
| Internal mammary artery | 183 (80.26%) | 107 (84.92%) | |
| Saphenous vein | 2.22 ± 0.64 | 2.25 ± 0.73 | |
| Graft patency | 0.522 | ||
| LIMA | 190 (83.33%) | 109 (86. 51%) | |
| SVG-D | 195 (85.53%) | 96 (76.19%) | |
| SVG-LCX/OM | 185 (81.14%) | 93 (73.81%) | |
| SVG-RCA/PDA | 163 (71.49%) | 84 (66.67%) | |
| Postoperative medication | 0.902 | ||
| Aspirin | 215 (94.30%) | 118 (93.65%) | |
| Statin | 185 (81.14%) | 98 (77.78%) | |
| Follow-up time (Mths) | 32.65 ± 15.84 | 37.52 ± 17.39 | 0.175 |
| Free of symptom | 123 (53.94%) | 56 (44.44%) | 0.087 |
| Incomplete revascularization | 112 (49.12%) | 70 (55.56%) | 0.125 |
Characteristics of lesion distribution. Preoperative and postoperative analyses of CTO distribution.
| Vessel | Pre-CABG ( | Post-CABG ( |
|---|---|---|
| LM | 0 (0%) | 3 (0.85%) |
| LAD | 38 (10.73%) | 69 (19.47%) |
| LCX | 22 (6.22%) | 38 (10.73%) |
| RCA | 53 (14.97%) | 76 (21.47%) |
| Multi vessels | 11 (3.12%) | 64 (18.08%) |
Distribution of new CTO in native vessels.
| Vessel | New CTO in native vessels ( |
|---|---|
| LM | 3 (2.38%) |
| LAD | 31 (24.6%) |
| LCX | 16 (12.7%) |
| RCA | 23 (18.25%) |
| Multivessels | 53 (42.06%) |
Disease progression in native vessels.
| Vessel | Overall ( | No new CTO ( | New CTO ( |
|---|---|---|---|
| LM | 22 (2.38%) | 12 (2%) | 3 (0.85%) |
| LAD | 250 (26.6%) | 42 (7.11%) | 69 (19.49%) |
| LCX | 129 (13.7%) | 17 (2.97%) | 38 (10.73%) |
| RCA | 171 (18.25%) | 37 (6.53%) | 40 (11.47%) |
Predictors for new native-vessel occlusion.
| Variables | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| OR | 95% CI |
| OR | 95% CI |
| |
| DM | 1.57 | 1.01–2.43 | 0.044 | 1.86 | 1.34–2.97 | 0.04 |
| Current smoking | 2.95 | 1.51–5.75 | 0.001 | 2.67 | 2.60–2.74 | 0.01 |
| Ejection fraction | 2.16 | 1.19–3.92 | 0.010 | 1.76 | 1.04–2.97 | 0.04 |
| Creatinine | 1.35 | 0.91–1.97 | 0.079 | |||
| Severe stenosis (≥70%) | 3.85 | 2.16–6.87 | 0.001 | 3.65 | 2.55–5.24 | 0.01 |